Lozano R M, Jiménez M, Santoro J, Rico M, Giménez-Gallego G
Centro de Investigaciones Biológicas (C.S.I.C.), Velázquez 144, Madrid, 28006, Spain.
J Mol Biol. 1998 Sep 4;281(5):899-915. doi: 10.1006/jmbi.1998.1977.
Recent data show that anti-angiogenesis may provide a promising route to treat cancer. Fibroblast growth factors (FGFs) are powerful angiogenic polypeptides, whose mitogenic activity requires the presence of heparin-like compounds. It has been shown that angiogenesis promoted by FGFs on inhibition by monoclonal antibodies and antisense targeting can also inhibit tumour growth. Derivatives of suramin, a polysulfonated binaphthyl urea and binaphthylsulfonated derivatives of distamycin, suradistas, constitute an important group of potential anti-cancer agents. These compounds compete with heparin in forming tight complexes with FGFs. This inhibits the recognition of these growth factors by their tyrosine kinase membrane receptors thereby suppressing their angiogenic activity. Here we show that 1,3,6-naphthalenetrisulfonate, a common chemical function of the suramins and suradistas with the highest anti-angiogenic activity inhibits the mitogenic activity of acidic fibroblast growth factor, and that this inhibition is relieved by increasing concentrations of heparin in the assay. We have also solved the three-dimensional structure in solution of the protein complexed to this compound. The structural data provide clues that may help in understanding the inhibitory effect of suramins and suradistas, and could contribute to the development of new anti-tumoral drugs.
近期数据表明,抗血管生成可能为癌症治疗提供一条有前景的途径。成纤维细胞生长因子(FGFs)是强大的血管生成多肽,其促有丝分裂活性需要类肝素化合物的存在。研究表明,FGFs促进的血管生成在被单克隆抗体抑制以及反义靶向作用下也能抑制肿瘤生长。苏拉明的衍生物,一种多磺酸化联萘脲以及双萘磺化的偏端霉素衍生物,苏拉地斯塔,构成了一类重要的潜在抗癌药物。这些化合物在与FGFs形成紧密复合物时与肝素竞争。这抑制了这些生长因子被其酪氨酸激酶膜受体识别,从而抑制它们的血管生成活性。在此我们表明,1,3,6 -萘三磺酸盐,一种苏拉明和苏拉地斯塔具有最高抗血管生成活性的常见化学官能团,抑制酸性成纤维细胞生长因子的促有丝分裂活性,并且在测定中增加肝素浓度可缓解这种抑制作用。我们还解析了与该化合物复合的蛋白质在溶液中的三维结构。结构数据提供了有助于理解苏拉明和苏拉地斯塔抑制作用的线索,并可能有助于开发新的抗肿瘤药物。